VYNE Therapeutics Inc. (VYNE)

NASDAQ: VYNE · IEX Real-Time Price · USD
2.220
-0.010 (-0.45%)
Mar 1, 2024, 4:30 PM EST - Market closed
-0.45%
Market Cap 31.30M
Revenue (ttm) 354,000
Net Income (ttm) -32.21M
Shares Out 13.96M
EPS (ttm) -9.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,975
Open 2.180
Previous Close 2.230
Day's Range 2.110 - 2.250
52-Week Range 1.670 - 8.730
Beta 1.32
Analysts Strong Buy
Price Target 7.38 (+232.43%)
Earnings Date Feb 29, 2024

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 12
Stock Exchange NASDAQ
Ticker Symbol VYNE
Full Company Profile

Financial Performance

In 2022, VYNE's revenue was $477,000, a decrease of -48.76% compared to the previous year's $931,000. Losses were -$23.21 million, -68.35% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is $7.38, which is an increase of 232.43% from the latest price.

Price Target
$7.38
(232.43% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inno...

3 days ago - GlobeNewsWire

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...

5 days ago - GlobeNewsWire

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and...

11 days ago - GlobeNewsWire

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Other symbols: ALVRGRIIBIO
6 weeks ago - Benzinga

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...

7 weeks ago - GlobeNewsWire

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...

2 months ago - GlobeNewsWire

Menlo Ventures Raises $1.35B for AI Investments

Menlo Ventures Partner Matt Murphy joins Caroline Hyde and Ed Ludlow to discuss the firm's latest funding to focus on nascent AI startups and early-stage investments, and explains why he sees generati...

3 months ago - Bloomberg Technology

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025

3 months ago - GlobeNewsWire

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE's clinical development plans

4 months ago - GlobeNewsWire

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025 Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025

4 months ago - GlobeNewsWire

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...

4 months ago - GlobeNewsWire

VYNE Therapeutics Announces Private Placement of $88 Million

Transaction provides $88 million to fund VYNE's clinical development programs for VYN201 and VYN202 through the end of 2025 Transaction provides $88 million to fund VYNE's clinical development program...

4 months ago - GlobeNewsWire

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...

4 months ago - GlobeNewsWire

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inn...

6 months ago - GlobeNewsWire

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023

7 months ago - GlobeNewsWire

VYNE Therapeutics to Attend BIO International Convention

BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innov...

10 months ago - GlobeNewsWire

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023

10 months ago - GlobeNewsWire

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development

10 months ago - GlobeNewsWire

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and...

11 months ago - GlobeNewsWire

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and...

1 year ago - GlobeNewsWire

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inn...

1 year ago - GlobeNewsWire

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial

1 year ago - GlobeNewsWire

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, inno...

1 year ago - GlobeNewsWire

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and...

1 year ago - GlobeNewsWire

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study

1 year ago - GlobeNewsWire